β-Lactam type molecular scaffolds for antiproliferative activity: Synthesis and cytotoxic effects in breast cancer cells

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 23, Issue 5, 2008, Pages 668-685

  Meegan, Mary J ^a   Carr, Miriam ^a   Knox, Andrew J S ^a,b   Zisterer, Daniela M ^b   Lloyd, David G ^b  

^a University College Dublin   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Lactam; Antiproliferative activity; Azetidin 2 one; SERMs

Indexed keywords

3 [1 HYDROXY 1 (3 HYDROXYPHENYL)ETHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [1 HYDROXY 1 (4 HYDROXYPHENYL)ETHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [1 HYDROXY 3 (4 HYDROXYPHENYL)1 METHYLALLYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [1 HYDROXY [3 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [1 HYDROXY [4 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [[4 (2 DIETHYLAMINOETHOXY)PHENYL]HYDROXYMETHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [[4 (2 DIETHYLAMINOETHOXY)PHENYL]HYDROXYMETHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; 3 [[4 (2 DIMETHYLAMINOETHOXY)PHENYL]HYDROXYMETHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [[4 (2 DIMETHYLAMINOETHOXY)PHENYL]HYDROXYMETHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; 3 [HYDROXY (2 HYDROXYNAPHTHALEN 1 YL)METHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (2 HYDROXYPHENYL)METHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (3 HYDROXYPHENYL)METHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (3 HYDROXYPHENYL)PHENYLMETHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (4 HYDROXYNAPHTHALEN 1 YL)METHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (4 HYDROXYPHENYL)METHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY (4 HYDROXYPHENYL)PHENYLMETHYL] 1,4 BIS (4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [2 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [3 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 MORPHOLIN 4 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 MORPHOLIN 4 YL)ETHOXY]PHENYL]METHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 PIPERIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 PIPERIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 [(2 PYRROLIDIN 1 YL)ETHOXY]PHENYL]METHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; 3 [HYDROXY [4 [2 (1 METHYLPYRROLIDIN 2 YL)ETHOXY]PHENYL]METHYL] 1,4 BIS(4 METHOXYPHENYL)AZETIDIN 2 ONE; 3 [HYDROXY [4 [2 (1 METHYLPYRROLIDIN 2 YL)ETHOXY]PHENYL]METHYL] 1,4 DIPHENYLAZETIDIN 2 ONE; ANTINEOPLASTIC AGENT; BETA LACTAM DERIVATIVE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BETA-LACTAMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DESIGN; FEMALE; HUMANS; MOLECULAR CONFORMATION; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53249113228     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802469127     Document Type: Article

References (48)

1. MacGregor, JI and Jordan, VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev, 50:2, pp. 151-196.
2. Jordan, VC (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem, 46:6, pp. 883-908.
3. Jordan, VC (2003) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem, 46:7, pp. 1081-1111.
4. Ariazi, EA, Ariazi, JL, Cordera, F. and Jordan, VC (2006) Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem, 6:3, pp. 181-202.
5. Grese, TA, Cho, S., Finley, DR, Godfrey, AG, Jones, CD, Lugar 3rd, CW, Martin, MJ, Matsumoto, K., Pennington, LD, Winter, MA, Adrian, MD, Cole, HW, Magee, DE, Phillips, DL, Rowley, ER, Short, LL, Glasebrook, AL and Bryant, HU (1997) Structure-activity relationships of selective estrogen receptor modulators: Modifications to the 2-arylbenzothiophene core of raloxifene. J Med Chem, 40:2, pp. 146-167.
6. Fisher, B., Costantino, JP, Wickerham, DL, Redmond, CK, Kavanah, M., Cronin, WM, Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L. and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 90:18, pp. 1371-1388.
7. Ahmed, S. (1998) Review of the molecular modelling studies of the cytochrome P-450 estrogen synthetase enzyme, aromatase. Drug Des Discov, 15:4, pp. 239-252.
8. Robertson, JF (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol, 79:1, pp. 209-212.
9. Stearns, V., Davidson, NE and Flockhart, DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J, 4:3, pp. 143-153.
10. Jensen, J., Kitlen, JW, Briand, P., Labrie, F. and Lykkesfeldt, AE (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol, 84:4, pp. 469-478.
11. Kijima, I., Itoh, T. and Chen, S. (2005) Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen. J Steroid Biochem Mol Biol, 97:4, pp. 360-368.
12. Brodie, AM, Lu, Q., Long, BJ, Fulton, A., Chen, T., Macpherson, N., DeJong, PC, Blankenstein, MA, Nortier, JW, Slee, PH, van de Ven, J., van Gorp, JM, Elbers, JR, Schipper, ME, Blijham, GH and Thijssen, JH (2001) Aromatase and COX-2 expression in human breast cancers. J Steroid Biochem Mol Biol, 79:15, pp. 41-47.
13. Gustafsson, JA (1999) Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol, 163:3, p. 379.
14. Pearce, ST and Jordan, VC (2004) The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol, 50:1, pp. 3-22.
15. Bardin, A., Boulle, N., Lazennec, G., Vignon, F. and Pujol, P. (2004) Loss of ERbeta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer, 11:3, p. 537.
16. Shiau, AK, Barstad, D., Loria, PM, Cheng, L., Kushner, PJ, Agard, DA and Greene, GL (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95:7, pp. 927-937.
17. Brzozowski, AM, Pike, AC, Dauter, Z., Hubbard, RE, Bonn, T., Engstrom, O., Ohman, L., Greene, GL, Gustafsson, JA and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature, 389:6652, pp. 753-758.
18. Pike, AC, Brzozowski, AM, Hubbard, RE, Bonn, T., Thorsell, AG, Engstrom, O., Ljunggren, J., Gustafsson, JA and Carlquist, M. (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J, 18:17, pp. 4608-4618.
19. Wu, YL, Yang, X., Ren, Z., McDonnell, DP, Norris, JD, Willson, TM and Greene, GL (2005) Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell, 18:4, p. 413.
20. Pike, AC, Brzozowski, AM, Walton, J., Hubbard, RE, Thorsell, AG, Li, YL, Gustafsson, JA and Carlquist, M. (2001) Structural insights into the mode of action of a pure antiestrogen. Structure, 9:2, pp. 145-153.
21. Lloyd, DG, Hughes, RB, Zisterer, DM, Williams, DC, Fattorusso, C., Catalanotti, B., Campiani, G. and Meegan, MJ (2004) Benzoxepin-derived estrogen receptor modulators: A novel molecular scaffold for the estrogen receptor. J Med Chem, 47:23, pp. 5612-5615.
22. Lloyd, DG, Smith, HM, O'Sullivan, T, Zisterer, DM and Meegan, MJ (2005) Synthesis, structure-activity realtionships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators. Med Chem, 1:4, p. 335.
23. Meegan, MJ, Barrett, I., Zimmermann, J., Knox, AJ, Zisterer, DM and Lloyd, DG (2007) Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: Synthesis and antagonistic effects in breast cancer cells. J Enzyme Inhib Med Chem, 22:5, pp. 655-666.
24. Lloyd, DG, Smith, HM, O'Sullivan, T., Knox, AS, Zisterer, DM and Meegan, MJ (2006) Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: Synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists. Med Chem, 2:2, pp. 147-168.
25. Knox, AJ, Meegan, MJ and Lloyd, DG (2006) Estrogen receptors: Molecular interactions, virtual screening and future prospects. Curr Top Med Chem, 6:3, pp. 217-243.
26. Kim, S., Wu, JY, Birzin, ET, Frisch, K., Chan, W., Pai, LY, Yang, YT, Mosley, RT, Fitzgerald, PM, Sharma, N., Dahllund, J., Thorsell, AG, DiNinno, F., Rohrer, SP, Schaeffer, JM and Hammond, ML (2004) Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators. J Med Chem, 47:9, pp. 2171-2175.
27. Gennari, L. (2006) Lasofoxifene: A new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc), 42:6, pp. 355-367.
28. Stauffer, SR, Huang, YR, Aron, ZD, Coletta, CJ, Sun, J., Katzenellenbogen, BS and Katzenellenbogen, JA (2001) Triarylpyrazoles with basic side chains: Development of pyrazole-based estrogen receptor antagonists. Bioorg Med Chem, 9:1, p. 151.
29. Renaud, J., Bischoff, SF, Buhl, T., Floersheim, P., Fournier, B., Geiser, M., Halleux, C., Kallen, J., Keller, H. and Ramage, P. (2005) Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands. J Med Chem, 48:2, pp. 364-379.
30. Labrie, F., Labrie, C., Belanger, A., Simard, J., Gauthier, S., Luu-The, V., Merand, Y., Giguere, V., Candas, B., Luo, S., Martel, C., Singh, SM, Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L. and Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol, 69:1, pp. 51-84.
31. Banik, BK and Becker, FF (2001) Synthesis, electrophilic substitution and structure-activity relationship studies of polycyclic aromatic compounds towards the development of anticancer agents. Curr Med Chem, 8:12, pp. 1513-1533.
32. Banik, BK, Becker, FF and Banik, I. (2004) Synthesis of anticancer beta-lactams: Mechanism of action. Bioorg Med Chem, 12:10, pp. 2523-2528.
33. Setti, EL, Davis, D., Janc, JW, Jeffery, DA, Cheung, H. and Yu, W. (2005) 3,4-disubstituted azetidinones as selective inhibitors of the cysteine protease cathepsin K. Exploring P3 elements for potency and selectivity. Bioorg Med Chem Lett, 15:5, pp. 1529-1534.
34. Veinberg, G., Vorona, M., Shestakova, I., Kanepe, I., Zharkova, O., Mezapuke, R., Turovskis, I., Kalvinsh, I. and Lukevics, E. (2000) Synthesis and antitumor activity of selected 7-alkylidene substituted cephems. Bioorg Med Chem, 8:5, pp. 1033-1040.
35. Veinberg, G., Shestakova, I., Vorona, M., Kanepe, I. and Lukevics, E. (2004) Synthesis of antitumor 6-alkylidenepenicillanate sulfones and related 3-alkylidene-2-azetidinones. Bioorg Med Chem Lett, 14:1, pp. 147-150.
36. Burnett, DA (2004) Beta-lactam cholesterol absorption inhibitors. Curr Med Chem, 11:14, pp. 1873-1887.
37. Adlington, RM, Baldwin, JE, Becker, GW, Chen, B., Cheng, L., Cooper, SL, Hermann, RB, Howe, TJ, McCoull, W., McNulty, AM, Neubauer, BL and Pritchard, GJ (2001) Design, synthesis, and proposed active site binding analysis of monocyclic 2-azetidinone inhibitors of prostate specific antigen. J Med Chem, 44:10, pp. 1491-1508.
38. Sutton, JC, Bolton, SA, Davis, ME, Hartl, KS, Jacobson, B., Mathur, A., Ogletree, ML, Slusarchyk, WA, Zahler, R., Seiler, SM and Bisacchi, GS (2004) Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett, 14:9, pp. 2233-2239.
39. Masui, M. and Ohmuri, H. (1972) Aniodic oxidation of Schiff bases. Part I. Oxidation of N-benzylidene-p-anisidines in acetonitrile. J Chem Soc Perkin Trans 2, pp. 1882-1886.
40. Balachandran, KS, Bhatnagar, I. and George, MV (1968) Oxidation by metal oxides. IV. Oxidation of organic compounds using nickle peroxide. J Org Chem, 33, pp. 3891-3895.
41. Palomo, C., Cossio, FP, Arrieta, A., Odriozola, JM, Oiarbide, M. and Ontoria, JM (1989) The Reformatsky type reaction of Gilman and Speeter in the preparation of valuable beta-lactams in carbapenem synthesis-scope and synthetic utility. J Org Chem, 54:24, pp. 5736-5745.
42. Otto, HH and Mayrhofer, R. (1983) Stereochemistry of dehydration and halogenation of alpha-R-star and alpha-S-star isomeric 3-(alpha-hydroxybenzyl)-1,4-diphenyl-2-azetidinones. Liebigs Ann Chem, pp. 1162-1168.
43. Otto, HH, Mayrhofer, R. and Bergmann, HJ (1983) Synthesis and stereochemistry of 3-(a-hydroxybenzyl)-1,4-diphenyl-2-azetidinones. Liebigs Ann Chem, pp. 1152-1161.
44. Palomo, C., Aizpurua, JM, Ganboa, I. and Oiarbide, M. (2004) Asymmetric synthesis of beta-lactams through the Staudinger reaction and their use as building blocks of natural and nonnatural products. Curr Med Chem, 11:14, pp. 1837-1872.
45. Overk, CR, Peng, KW, Asghodom, RT, Kastrati, I., Lantvit, DD, Qin, Z., Frasor, J., Bolton, JL and Thatcher, GR (2007) Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Chem Med Chem, 2:10, pp. 1520-1526.
46. McKie, JA, Bhagwat, SS, Brady, H., Doubleday, M., Gayo, L., Hickman, M., Jalluri, RK, Khammungkhune, S., Kois, A., Mortensen, D., Richard, N., Sapienza, J., Shevlin, G., Stein, B. and Sutherland, M. (2004) Lead identification of a potent benzopyranone selective estrogen receptor modulator. Bioorg Med Chem Lett, 14:13, pp. 3407-3410.
47. Littlefield, BA, Gurpide, E., Markiewicz, L., McKinley, B. and Hochberg, RB (1990) A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: Estrogenic action of delta 5 adrenal steroids. Endocrinology, 127:6, pp. 2757-2762.
48. Sobolev, V., Sorokine, A., Prilusky, J., Abola, EE and Edelman, M. (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics, 15:4, pp. 327-332.